Ndisang Joseph Fomusi, Wang Rui
Department of Physiology, University of Saskatchewan, Saskatoon, SK, Canada.
J Hypertens. 2003 Jun;21(6):1117-24. doi: 10.1097/00004872-200306000-00011.
Vascular contractility and blood pressure (BP) are regulated by soluble guanylyl cyclase (sGC) and cyclic guanosine monophosphate (cGMP) pathway, which can be influenced by heme oxygenase (HO)-derived carbon monoxide (CO). The age-related changes in sGC/cGMP pathway in tail artery smooth muscle cells (SMCs) in hypertension have not been systematically investigated.
In the present study, spontaneously hypertensive rats (SHR) of 4, 8, and 20 weeks old were used. The basal and hemin-modulated levels of sGC and cGMP in tail artery tissues were examined.
Although BP of 20-week SHR was significantly elevated, sGC and cGMP levels were unaltered compared with age-matched Wistar-Kyoto rats (WKY). The levels of sGC and cGMP were significantly lower in 4- and 8-week SHR compared with age-matched WKY although BP of 4-week SHR was normotensive. Hemin administration resulted in a significant decrease in BP in 8-week (158.7 +/- 2.4 versus 123.5 +/- 1.3 mmHg, P < 0.01), but not in pre-hypertensive (4 weeks) or 20-week SHR or WKY at all ages. Coincidently, sGC and cGMP levels in 8-week SHRs were significantly elevated and so did the expression levels of HO-1. Hemin treatment did not increase the cyclic adenosine monophosphate (cAMP) content of tail artery from 8-week SHR. The constitutive HO-2 levels remained unchanged in 8- and 20-week SHR and age-matched WKY.
The HO-activity inhibitor, chromium mesoporphyrin, abolished the BP-lowering and HO- stimulating effects of hemin in young SHR. Our results suggest that alteration in sGC/cGMP pathway in vascular SMCs precedes the occurrence of hypertension but returns to normal once hypertension is fully manifested.
血管收缩性和血压(BP)受可溶性鸟苷酸环化酶(sGC)和环磷酸鸟苷(cGMP)途径调节,该途径可受血红素加氧酶(HO)衍生的一氧化碳(CO)影响。高血压状态下尾动脉平滑肌细胞(SMC)中sGC/cGMP途径的年龄相关变化尚未得到系统研究。
在本研究中,使用了4周、8周和20周龄的自发性高血压大鼠(SHR)。检测尾动脉组织中sGC和cGMP的基础水平及血红素调节水平。
尽管20周龄SHR的血压显著升高,但与年龄匹配的Wistar-Kyoto大鼠(WKY)相比,sGC和cGMP水平未改变。与年龄匹配的WKY相比,4周龄和8周龄SHR的sGC和cGMP水平显著降低,尽管4周龄SHR的血压正常。给予血红素后,8周龄SHR的血压显著降低(158.7±2.4对123.5±1.3 mmHg,P<0.01),但在高血压前期(4周)或20周龄SHR以及所有年龄段的WKY中均未降低。巧合的是,8周龄SHR中的sGC和cGMP水平显著升高,HO-1的表达水平也升高。血红素处理未增加8周龄SHR尾动脉的环磷酸腺苷(cAMP)含量。8周龄和20周龄SHR以及年龄匹配的WKY中组成型HO-2水平保持不变。
HO活性抑制剂中卟啉铬消除了血红素对年轻SHR的降压和HO刺激作用。我们的结果表明,血管SMC中sGC/cGMP途径的改变先于高血压的发生,但一旦高血压完全显现则恢复正常。